<DOC>
	<DOCNO>NCT02807415</DOCNO>
	<brief_summary>The academic investigator - initiated trial evaluate postapproval set whether , yes , extent variability , treatment lumacaftor combination ivacaftor reverse p.Phe508del CFTR - mediate basic defect p.Phe508del homozygous subject cystic fibrosis real life condition .</brief_summary>
	<brief_title>ICM Evaluate Activation p.Phe508del-CFTR Lumacaftor Combination With Ivacaftor</brief_title>
	<detailed_description>Study design . This academic investigator - initiated trial resolve key issue whether , yes , extent variability , treatment lumacaftor combination ivacaftor ( Orkambi® ) reverse p.Phe508del CFTR - mediate basic defect p.Phe508del homozygous subject cystic fibrosis real life condition . Each p.Phe508del homozygous subject function control . Baseline measurement perform within 4-week interval prior start oral treatment lumacaftor + ivacaftor . According phase 3 study result week 4 gain FEV1 level , drug level steady state reversible initial reduction lung function resolve . Thus second assessment perform initial steady state day 10 - 14 week initiation oral treatment lumacaftor + ivacaftor . At day investigation basic defect assess Gibson-Cooke pilocarpine iontophoresis sweat test , nasal transepithelial potential difference measurement ( NPD ) intestinal current measurement ( ICM ) . Moreover lung function measure spirometry . The plasma concentration lumacaftor , ivacaftor , metabolite determine safety oral treatment Orkambi assess accord prescribe information . Study participant request record administration Orkambi® date time 7 day schedule visit perform functional CFTR assay . Orkambi® administer within 30 minute consume fat-containing food accord FDA-approved patient label prescribe information . Subjects give diary record time dose administration Orkambi® seven day schedule visit . Measures recruitment bias . The local patient database three site search subject fulfil inclusion criterion . After subject remove list fulfill one exclusion criterion , eligible subject randomly assign rank number . Subjects contact sequence appear rank number list . Statistical analysis . The sample size estimate base absolute change baseline cumulative chloride secretory ion current response forskolin/IBMX carbachol ICM outcome measure CFTR function . Assuming nominal type I error 0.05 power 0.8 , 125 33 subject need demonstrate treatment effect 5 % 10 % , respectively . Thus even modest change basis defect demonstrate recruited cohort 125 subject incomplete data set half subject . To evaluate change lung function CFTR biomarkers prior treatment Orkambi® , Student 's test , pair Student 's test Wilcoxon signed-rank test perform appropriate . Relationships CFTR biomarkers first assess Pearson product-moment correlation coefficient case whole data set explore canonical correlation analysis . Furthermore sensitivity specificity CFTR biomarkers detect treatment effect determine . The biostatistician KKS Heidelberg assist statistical evaluation . Ethical consideration . Orkambi® approve treatment subject cystic fibrosis , homozygous p.Phe508del mutation . Drug handle safety control execute accord BfArM-approved patient label full prescribe information . Study protocol inform consent form approve ethic committee . Prior investigation patient parental guide ( applicable ) inform background , objective , schedule assessment study . Each adult age 18 year old must sign date study-specific informed-consent form study-specific procedure perform . Subjects age 12 - 17 year must assent participate study subject 's parent legal guardian must sign date study-specific informed-consent form study-specific procedure perform . Sweat test NPD safe procedure . Burns iontophoresis , injury placement subcutaneous electrode NPD diuresis induce swallow amiloride young subject nasal superfusion observe three site . The collection rectal biopsy principally safe painless procedure . ICM perform Hannover Medical School . since 1995 . During 20 year bleeding observe five subject one require hospitalization . Haemorrhoids abnormal bleeding time contraindication ICM exclusion criterion participate study . Hence , exception low bleeding risk associate collection rectal biopsy study participant put risk . There direct benefit study participant , however , decision whether Orkambi® prescribe base solid data . Quality assurance . Sweat test , NPD , ICM sample ( blood , serum , plasma ) perform accord harmonize Standard Operating Procedures base protocol Clinical Trials Network European Cystic Fibrosis Society and/or Therapeutics Development Network Coordinating Center US Cystic Fibrosis Foundation and/or Hannover Unified Biobank . Pre-study hands-on meeting organize compare on-site execution protocol include sweat test , NPD , ICM , lung function test sampling , processing , storage serum plasma specimen . Sweat test subject domestic quality control trial . Local central reading perform NPD ICM tracing . The site long-standing expertise CFTR biomarkers train numerous domestic European site NPD ICM . - Subjects educate drug dose . A diary drug dosing ( date time ) fill 7 day prior day assessment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1. p.Phe508del homozygous subject age 12 year older cystic fibrosis 2 . FEV1 ≥ 40 % predict normal age , gender height ( Knudson standard ) FEV1 &gt; 35 % predict normal age , gender height baseline , stable lung function precede three month acute upper low respiratory infection pulmonary exacerbation precede four week 3 . Hematology , serum chemistry , coagulation result baseline clinically significant abnormality would interfere oral treatment Orkambi® study assessment , judge investigator 4 . Able understand comply protocol requirement , restriction , instruction likely complete study plan , judge investigator 5 . Willing remain stable medication regimen administration Orkambi® accord FDAapproved patient label prescribe information duration study participation 1 . History illness , opinion investigator , might confound result study pose additional risk administer Orkambi® 2 . An acute upper low respiratory infection pulmonary exacerbation baseline 3 . Advanced liver disease document sonography 4 . Abnormal liver function baseline , define ≥ 3 upper limit normal minimum 3 following : serum aspartate transaminase , serum alanine transaminase , gammaglutamyl transpeptidase , total bilirubin 5 . Abnormal blood creatine phosphokinase baseline 6 . Abnormal renal function baseline , define creatinine clearance &lt; 60 mL/min 7 . Comedication strong CYP3A inhibitor inducer 8 . Noncongenital lens opacity 9 . Haemorrhoids ( bleed risk take rectal suction biopsy ICM ) 10 . History nasal surgery remove respiratory epithelium 11 . Topical treatment nostril 3 day prior baseline 12 . Disturbing nasal aspect secretion , erythema , crustae , ulcera , edema baseline 13 . Participation clinical study involve administration CFTR modulator 14 . History solid organ haematological transplantation 15 . History alcohol , medication , illicit drug abuse Exclusion criterion 1 , 3 , 4 , 5 , 6 , 7 8 refer know risk factor treatment Orkambi® .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>CFTR modulation</keyword>
	<keyword>sweat test</keyword>
	<keyword>intestinal current measurement , ICM</keyword>
	<keyword>nasal transepithelial potential difference measurement , NPD</keyword>
</DOC>